Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers

Kalpa Patel, Erin C. Farlow, Anthony W. Kim, Bao Shiang Lee, Sanjib Basu, John S. Coon, David DeCresce, Lida Thimothy, Kelly A. Walters, Cristina Fhied, Christopher Chang, Ssu Hsien Chen, L. Penfield Faber, Philip Bonomi, Michael J. Liptay, Jeffrey A. Borgia

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

We recently reported the development of a multianalyte serum algorithm to identify nodal status in non-small cell lung cancer (NSCLC) patients facing an anatomic resection with curative intent. This study aims to enhance the overall performance characteristics of this test by adding autoantibody biomarkers identified through immunoproteomic discovery. More specifically, we used sera from 20 NSCLC patients to probe 2-D immunoblots of HCC827 lysates for tumor-associated autoantigens. Relevant differences in immunoreactivity associated with pathological nodal status were then identified via tandem mass spectrometry. Identified autoantigens were then developed into Luminex immunobead assays alongside a series of autoantigen targets relevant to early-disease detection. These assays were then used to measure circulating autoantibody levels in the identical cohort of NSCLC patients used in our original study. This strategy identified 11 autoantigens found primarily in patients with disease progression to the locoregional lymph nodes. Custom Luminex-based "direct-capture" assays (25 total; including autoantibody targets relevant to early-disease detection) were assembled to measure autoantibody levels in sera from 107 NSCLC patients. Multivariate classification algorithms were then used to identify the optimal combination of biomarkers when considered collectively with our original 6-analyte serum panel. The new algorithm resulting from this analysis consists of TNF-α, TNF-RI, MIP-1α and autoantibodies against Ubiquilin-1, hydroxysteroid-(17-β) -dehydrogenase, and triosephosphate isomerase. The inclusion of autoantibody biomarkers provided a dramatic improvement in the overall test performance characteristics, relative to the original test panel, including an 11% improvement in the classification efficiency.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalInternational Journal of Cancer
Volume129
Issue number1
DOIs
StatePublished - Jul 1 2011

Keywords

  • NSCLC
  • autoantibody
  • biomarkers
  • luminex
  • mass spectrometry
  • proteomics
  • serum

Fingerprint

Dive into the research topics of 'Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers'. Together they form a unique fingerprint.

Cite this